AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.67 |
Market Cap | 64.78M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -4.22 |
PE Ratio (ttm) | -1.11 |
Forward PE | n/a |
Analyst | Buy |
Ask | 4.74 |
Volume | 18,164 |
Avg. Volume (20D) | 358,791 |
Open | 4.88 |
Previous Close | 4.67 |
Day's Range | 4.63 - 4.88 |
52-Week Range | 4.21 - 20.00 |
Beta | undefined |
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for prote...
Analyst Forecast
According to 7 analyst ratings, the average rating for ANVS stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 432.49% from the latest price.
9 months ago · headlinesoftoday.com
Exploring Automotive Night Vision System Sector Trends Forecast, 2023-2032Market Research Report Automotive Night Vision System Market Size, Share, Competitive Landscape and Trend Analysis: Global Opportunity Analysis and Industry Forecast, 2023-2032 PORTLAND, PROVINCE: ORE...
11 months ago · seekingalpha.com
Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's ProspectsA small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson's disease (PD). 24-38% of patient anecdotes report a noticeable/measurab...